



Massachusetts General Hospital  
Corporate & Foundation Relations  
Office of Development

**PRIVATE FUNDING OPPORTUNITIES: NOV 24, 2017**

Please contact Corporate & Foundation Relations in the Office of Development at [devcfr@mgh.harvard.edu](mailto:devcfr@mgh.harvard.edu) if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

**1. ASLMS Research Grant Program, American Society for Laser Medicine and Surgery (ASLMS)**

The ASLMS supports research projects designed to foster the development and use of lasers and other related technologies in medical and surgical applications. While the best research projects will be given priority for funding, a concerted effort will be made to award a balance of basic science and clinical research. The primary purpose of the ASLMS Research Grant Program is to conduct research which can be applied to medical and surgical care of patients. Preference will be given to proposed research projects which have a direct implication for medical or surgical applications.

Award Amount: \$70,000 for 1 year

Indirect Costs: 10%

Pre-Application Deadline: Jan 12, 2018

Website: <http://www.aslms.org/grants/researchgrantappguide.shtml>

**2. HIVMA Clinical Fellowship, Infectious Diseases Society of America (IDSA)/HIV Medicine Association (HIVMA)**

The Fellowship program supports newly trained physicians with gaining HIV clinical experience working with medically underserved patient populations. The goal of the program is to boost the population of HIV physicians and strengthen the commitment to provide clinical care to HIV-infected patients in minority communities.

During the fellowship year, fellows must:

- Work in a clinical setting with a large minority patient population in the USA.



---

Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <[arobb@mgh.harvard.edu](mailto:arobb@mgh.harvard.edu)> to schedule an individual consultation or group training session.

- Manage at least 30 HIV patients over the course of their clinical training experience, in both inpatient and outpatient settings.\*
- Engage in a mix of didactic and clinical experiences designed to provide the fellow with expertise in the longitudinal care of HIV-infected patients and treatment of common co-morbidities and co-infections, such as hepatitis C, substance use and mental illness.
- Attend the 2018 IDWeek conference that will take place October 3 to 7 in San Francisco, CA (HIVMA will cover all expenses).
- Participate in a follow-up questionnaire after the completion of the fellowship year.

\*Fellows may elect to spend up to 2 months of their Fellowship at another approved institution, clinic or practice to supplement their clinical experience. Sponsoring institutions must have an adequate census of HIV patients to ensure an adequate clinical experience.

Award Amount: Grants are made to the institution to support a stipend of \$60,000 plus additional funding to cover fringe benefits for one year. Malpractice insurance is not covered by this grant. An additional \$10,000 is paid to the institution to offset administrative costs and to provide for additional educational opportunities.

Indirect Costs: Unspecified

Application Deadline: Jan 8, 2018

Website:

[http://www.hivma.org/HIVMA/Career\\_Training/Minority\\_Clinical\\_Fellowship\\_Apply\\_Online/](http://www.hivma.org/HIVMA/Career_Training/Minority_Clinical_Fellowship_Apply_Online/)

### **3. Target Identification in Lupus Grant (TIL Grants), Lupus Research Alliance**

Under the Target Identification in Lupus (TIL) grant program, investigators receive a cash award to remove the barriers to new treatments and a possible cure. All research funded under the TIL program is based on realizable goals and designed for "translational" research - discoveries that become useful therapies in the near future, moving quickly from the laboratory to the patient's bedside.

The goals of the TIL grant program are to: (1) characterize key steps in the pathogenesis of the disease that will allow for the development of new therapeutic agents; (2) promote basic and clinical research studies to identify and/or better characterize promising lead compounds for lupus treatment; and (3) support research that facilitates the clinical evaluation of innovative approaches to the prevention or treatment of lupus and its complications.

This research is intended to be highly focused on lupus and, as such, should lead directly to knowledge that will facilitate drug discovery and/or testing of new treatments. These therapies may be used to treat systemic or organ-specific manifestations of lupus, although they may find applicability in the setting of other autoimmune or inflammatory illnesses.

As the goal of this program is to advance the treatment of lupus, any research funded must be based on realizable goals for translation into therapeutic discovery programs. Targets can

include small molecules, biologic agents, vaccines, gene therapy, as well as novel approaches in public health and risk reduction.

The Lupus Research Alliance particularly welcomes applications proposing research that will apply knowledge gained in other disease areas (e.g., other autoimmune and inflammatory conditions, cancer, metabolic diseases) to mechanisms relevant to lupus.

The TIL grant program will fund research that will accelerate the development of new treatments of lupus. As such, these grants should be innovative in direction and utilize state-of-the-art techniques. Fundamental studies in genetics, immunology, cell biology and molecular biology to identify and characterize molecular systems must be oriented towards the development of drugs that would prevent and/or ameliorate clinical signs and symptoms of lupus.

These studies can be initiated or conducted in either humans or animals, although any work on animals must include a plan for extension and verification in patient populations. Studies working towards the identification or development of lead therapeutic compounds for lupus must provide a clear scientific rationale for the compound(s) under investigation, and a research plan that would allow for a definitive decision regarding the viability of the compound(s) as a therapeutic approach to lupus. Clinical studies to improve the ability to evaluate innovative therapies in lupus may focus on the development of systems or processes that enhance the ability to obtain reliable and timely answers to therapeutic questions in lupus.

TIL grants should lead to new insights into disease pathogenesis, advances in the development of innovative therapies under consideration for lupus, or improvements in the abilities to evaluate the outcome of lupus therapies. These proposals must demonstrate a strong orientation to the development and/or evaluation of new therapeutics. Thus, these grants differ from a conventional NIH R01 mechanism where a translational goal is not essential to the success of the grant. Applications submitted for the TIL grant program must be relevant to the purpose and goals of the program and the mission of the Lupus Research Alliance.

Award Amount: \$600,000 paid over 3 years

Indirect Costs: 8%

Application Deadline: Feb 9, 2018

Website: <https://www.lupusresearch.org/research/our-funded-research/funding-opportunities/>